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Transcriptional dysregulation of the MYC oncogene
is among the most frequent events in aggressive tu-
mor cells, and this is generally accomplished by
acquisition of a super-enhancer somewhere within
the 2.8 Mb TAD where MYC resides. We find that
these diverse cancer-specific super-enhancers,
differing in size and location, interact with the MYC
gene through a common and conserved CTCF bind-
ing site located 2 kb upstream of theMYC promoter.
Genetic perturbation of this enhancer-docking site in
tumor cells reduces CTCF binding, super-enhancer
interaction,MYC gene expression, and cell prolifera-
tion. CTCF binding is highly sensitive to DNA
methylation, and this enhancer-docking site, which
is hypomethylated in diverse cancers, can be inacti-
vated through epigenetic editing with dCas9-DNMT.
Similar enhancer-docking sites occur at other genes,
including genes with prominent roles in multiple can-
cers, suggesting a mechanism by which tumor cell
oncogenes can generally hijack enhancers. These
results provide insights into mechanisms that allow
a single target gene to be regulated by diverse
enhancer elements in different cell types.INTRODUCTION
Elevated expression of the c-MYC transcription factor occurs in
a broad spectrum of human cancers and is associated with tu-
mor aggression and poor clinical outcome (Berns et al., 1992;
Dang, 2012; Gabay et al., 2014; Grotzer et al., 2001). Activation
of theMYC gene, which encodes c-MYC, is a hallmark of cancer
initiation and maintenance. Dysregulation of MYC is often
achieved through the formation of large tumor-specific super-
enhancers in the region surrounding the MYC gene (Chapuy
et al., 2013; Fulco et al., 2016; Herranz et al., 2014; Hnisz
et al., 2013; Lin et al., 2016; Liu et al., 2015; Love´n et al., 2013;
Shi et al., 2013; Whyte et al., 2013; Zhang et al., 2016). These
large enhancer clusters differ in size, composition, and distance
from the MYC promoter, yet all accomplish the same task ofC
This is an open access article undstimulating MYC overexpression across a broad spectrum of
tumors.
Selective gene activation is essential to the gene expression
programs that define both normal and cancer cells. During
gene activation, transcription factors (TFs) bind enhancer ele-
ments and regulate transcription from the promoters of nearby
or distant genes through physical contacts that involve looping
of DNA between enhancers and promoters (Bonev and Cavalli,
2016; Buecker and Wysocka, 2012; Bulger and Groudine,
2011; Fraser et al., 2015; M€ueller-Storm et al., 1989; Spitz,
2016; de Wit et al., 2013). The mechanisms that ensure that spe-
cific enhancers interact with specific promoters are not fully un-
derstood. Some enhancer-promoter interactions are likely deter-
mined by the nature of TFs bound at the two sites (Muerdter and
Stark, 2016; Weintraub et al., 2017).
Recent studies have revealed that specific chromosome
structures play important roles in gene control. Enhancer-pro-
moter interactions generally occur within larger chromosomal
loop structures formed by the interaction of CTCF proteins
bound to each of the loop anchors (Dekker and Mirny, 2016;
Fraser et al., 2015; Gibcus and Dekker, 2013; Gorkin et al.,
2014a; Hnisz et al., 2016a, 2018; Ji et al., 2016). These loop
structures, variously called topologically associated domains
(TADs), sub-TADs, loop domains, CTCF contact domains, and
insulated neighborhoods, tend to insulate enhancers and genes
within the CTCF-CTCF loops from elements outside those loops
(Dixon et al., 2012; Dowen et al., 2014; Franke et al., 2016; Hnisz
et al., 2016a, 2016b; Ji et al., 2016; Narendra et al., 2015; Nora
et al., 2012; Phillips-Cremins et al., 2013; Rao et al., 2014). Con-
straining DNA interactions within CTCF-CTCF loop structures in
this manner may facilitate proper enhancer-promoter contacts.
CTCF does not generally occupy enhancer and promoter ele-
ments (Cuddapah et al., 2009; Dixon et al., 2012; Dowen et al.,
2014; Handoko et al., 2011; Ji et al., 2016; Kim et al., 2007; Phil-
lips-Cremins et al., 2013; Rao et al., 2014; Rubio et al., 2008;
Tang et al., 2015). Another TF, YY1, generally binds to enhancers
and promoters and facilitates their interaction through YY1
dimerization (Weintraub et al., 2017). However, when CTCF
does bind these regulatory elements, it can also contribute to
enhancer-promoter interactions (Banani et al., 2017; Nora
et al., 2017; Splinter et al., 2006; Zuin et al., 2014).
Here, we investigate DNA looping structures in theMYC locus
in multiple cancers and identify a CTCF-occupied site at the
MYC promoter that facilitates docking with essentially anyell Reports 23, 349–360, April 10, 2018 ª 2018 The Author(s). 349
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
enhancers that are formed within the 2.8 Mb MYC locus. The
CTCF-occupied site at the MYC promoter, which we call the
MYC enhancer-docking site, can be abrogated by genetic and
epigenetic editing. Similar enhancer-docking sites occur at other
oncogenes. This suggests a mechanism by which tumor cells
can generally hijack enhancers and, with editing, a potential ther-
apeutic vulnerability.
RESULTS
Cell-Type-Specific MYC Enhancers Loop to a Common
Upstream CTCF Site
Previous studies have established that tumor cells acquire tu-
mor-specific super-enhancers at various sites throughout the
MYC locus (Figures 1A and S1A) (Bradner et al., 2017; Chapuy
et al., 2013; Gabay et al., 2014; Gro¨schel et al., 2014; Herranz
et al., 2014; Hnisz et al., 2013; Lin et al., 2016; Love´n et al.,
2013; Parker et al., 2013; Zhang et al., 2016; Shi et al., 2013),
but the mechanisms by which these diverse enhancer structures
control MYC are not clear. In one case, for example, a super-
enhancer located 2 Mb downstream of the MYC gene has
been shown to physically interact with MYC, but the mecha-
nisms responsible for this specific interaction are unclear (Shi
et al., 2013). To gain insights into the potential role of DNA
loop structures in gene control at the MYC locus, we generated
cohesin HiChIP data for HCT-116 cells and collected published
DNA interaction data for three other cancer cell types for com-
parison (Figure 1B; Tables S1 and S5) (Hnisz et al., 2016a;
Pope et al., 2014). Among the DNA loop structures observed in
these datasets, a large 2.8 Mb DNA loop was evident in all four
cell types. This loop connects CTCF sites encompassing the
MYC gene and qualifies as an insulated neighborhood. The
DNA anchor sites of this 2.8 Mb DNA loop occur at the bound-
aries of a TAD found in all cells (Figure S1B). The MYC TAD en-
compasses a region previously described as a ‘‘gene desert,’’
because this large span of DNA contains no other annotated pro-
tein-coding genes (Montavon and Duboule, 2012; Ovcharenko
et al., 2005).
While all cells examined appear to share the TAD-spanning 2.8
Mb loop encompassing MYC, the loop structures within the
neighborhoodwere found to bemarkedly different among the tu-
mor types. The internal loops were dominated by interactions
between a MYC promoter-proximal CTCF site and the diverse
super-enhancers (Figures 1B and 1C). The major differences be-
tween these internal structures in the different tumor cells
involved the different positions of the tumor-specific super-
enhancer elements. Examination of Hi-C data for a broader
spectrum of tumor cell types suggests that tumor cells generally
have DNA contacts between the MYC promoter-proximal site
and other sites within the 2.8 Mb MYC TAD (Figure S1B). This
looping was not limited to cancer cells, because examination
of enhancer and promoter-capture Hi-C data in a variety of
normal cell types that express MYC (Javierre et al., 2016) re-
vealed that cell-type-specific enhancers do indeed loop to the
MYC proximal CTCF site (Figures S1C and S1D). This indicated
that this CTCF site is also used during normal development by
cell-type-specific enhancers to facilitate MYC expression and
cellular proliferation.350 Cell Reports 23, 349–360, April 10, 2018Further examination of theMYC promoter-proximal region re-
vealed three constitutive CTCF binding sites (Figure 1C). All
three sites were found to be occupied by CTCF in a wide variety
of normal cells and tumor cells, and this binding pattern is
shared across species (Figure S1C). Previous studies have
examined the role of CTCF binding at all three sites (Filippova
et al., 1996; Gombert and Krumm, 2009; Gombert et al., 2003;
Klenova et al., 1993; Rubio et al., 2008). The two sites located
within the MYC gene have been shown to play roles in MYC
transcript start site selection and in promoter-proximal pausing
of RNA polymerase II (Filippova et al., 1996). The CTCF binding
site located 2 kb upstream of the major transcription start site
has been reported to protect the promoter from methylation
and to be an insulator element (Gombert and Krumm, 2009;
Gombert et al., 2003). The DNA interaction data described
here, however, suggests that this upstream site dominates con-
nections with distal enhancer elements, as the majority of reads
in the DNA interaction data are associated with this site in all tu-
mor cells examined (Figures 1C and S1E). The 2 kb CTCF
binding site contains a number of putative CTCF binding motifs;
one of these most closely matches the canonical CTCF motif in
the JASPAR database (Sandelin et al., 2004) and occurs within
a highly conserved sequence (Figure 1D). These features, the
presence of CTCF sites in tumor super-enhancers, and the
ability of two CTCF-bound sites to be brought together through
CTCF homodimerization (Saldan˜a-Meyer et al., 2014; Yusufzai
et al., 2004) led us to further study the possibility that the
2 kb site has an enhancer-docking function critical to MYC
expression.
MYC Promoter Proximal CTCF Site Is Necessary for
Enhancer-Promoter Looping and High MYC Expression
To determine whether the putative enhancer-docking site plays
a functional role inMYC expression through DNA loop formation,
small perturbations of the CTCF binding site were generated in
both alleles of the tumor cell lines K562, HCT-116, Jurkat, and
MCF7 using clustered regularly interspaced short palindromic
repeats (CRISPR)/Cas9 (Figures 2A and 2B). Attempts at genetic
perturbation by transfection with constructs carrying CRISPR/
Cas9 with a guide RNA specifically targeting the CTCF motif up-
streamof theMYC gene did not yield viable clones. To allow cells
to continue to proliferate if the CTCF motif deletion was lethal,
cells were virally transduced with an exogenous MYC gene
driven by a phosphoglycerate kinase (PGK) promoter (Fig-
ure S2A). This construct contained sequence differences in the
30 UTR that allowed discrimination between the endogenous
and exogenous MYC mRNAs. Cells expressing this exogenous
MYC gene were then subjected to CRISPR/Cas9 perturbation.
Clones were selected with small deletions or insertions disrupt-
ing the canonical CTCF motif (Figures 2B and S2B) and these
cells were further characterized. CTCF chromatin immunopre-
cipitation quantative polymerase chain reaction (ChIP-qPCR)
showed complete loss of CTCF binding to this site in K562 and
HCT-116 cells and a 60%–70% reduction in CTCF binding at
this site in Jurkat and MCF7 cells (Figure 2C). RNA analysis re-
vealed a 70%–80% reduction of endogenous MYC mRNA in
the absence of the enhancer-docking site in all of these cell types
(Figure 2D). Furthermore, an inducible CRISPR/Cas9
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Figure 1. Cell-Type-Specific Super-Enhancers in the
MYC Locus Loop to a Common CTCF Site
(A) The 4.5 Mb region surrounding the MYC gene. The 2.8 Mb
TAD containingMYC and portions of the two adjacent TADs are
indicated with thick black horizontal lines. Super-enhancers
(data from Becket et al., 2016; Frietze et al., 2012; Lin et al.,
2012; Pope et al., 2014; Wang et al., 2011) are shown in colored
boxes for a panel of tumor cell lines that express MYC.
(B) Chromosome interaction data at the 3 MbMYC locus. For
HCT-116, SMC1 HiChIP interactions with an origami score of at
least 0.9 and a minimum PET count of 9 are shown as purple
arcs; the insulated neighborhood spanning interaction, which
encompasses the TAD, is shown as a blue arc (data from this
study). For MCF7, Pol II ChIA-PET interactions with an origami
score of at least 0.9 are shown as purple arcs; the insulated
neighborhood spanning interactions from CTCF ChIA-PET data
are shown in blue (data from ENCODE and Li et al., 2012). For
K562, RAD21 ChIA-PET interactions with an origami score of at
least 0.9 are shown as purple arcs; the insulated neighborhood
spanning interaction is shown in blue and has an origami
score of 0.44 (data from Heidari et al., 2014). For Jurkat, SMC1
ChIA-PET interactions with an origami score of at least 0.99 are
shown as purple arcs; the insulated neighborhood spanning
interactions are shown in blue (data from Hnisz et al., 2016a).
CTCF ChIP-seq peaks are depicted as purple rectangles,
super-enhancers are depicted as red rectangles, and typical
enhancers are depicted as gray rectangles (data from this
study; Hnisz et al., 2016a; Pope et al., 2014).
(C) CTCF ChIP-seq and SMC1 ChIA-PET read counts in the
MYC promoter regions. Purple tracks display CTCF ChIP-seq
signal in the four cell lines from (B). Light blue track displays the
read counts from read pileup of Jurkat SMC1 ChIA-PET data,
showing that the major peak of SMC1 ChIA-PET reads occurs
at the 2 kb CTCF site. Dark blue bars indicate CpG islands.
ChIP-seq read counts are shown in reads permillion sequenced
reads per base pair. ChIA-PET reads are shown as read counts
per base pair.
(D) The top panel depicts all putative CTCF binding motifs as
blue arrows, which indicate the orientation of the motif. The
CTCF motif depicted in dark blue occurs in the most conserved
region and shows the best match with consensus CTCF motif.
100 vertebrate conservation from the UCSC genome browser is
depicted in the middle panel. The JASPAR score for all the
motifs is indicated with blue bars. The position weight matrix for
the canonical JASPAR CTCF motif and the actual sequence is
shown below.
See also Figure S1.
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Figure 2. Perturbation of the Core CTCFMotif
in the MYC CTCF Loop-Anchor Reduces
CTCF Occupancy and MYC Expression
(A) Schematic representation of the experiment.
HCT-116, K562, Jurkat, and MCF7 cells were
transduced with a construct expressing MYC under
a PGK promoter and selected for successful inte-
gration. These cells were then transiently transfected
with plasmid carrying Cas9 and a gRNA targeting the
CTCF binding motif. Positive cells were identified
and selected using fluorescence-activated cell
sorting (FACS). These cells were multiplied, and
clonal populations were characterized.
(B) The DNA sequences in the vicinity of the core
CTCF motif and the mutations generated in clonal
populations of K562, HCT-116, Jurkat, and MCF7
cell lines. The reference (WT, wild-type) sequence
highlighted in blue is complementary to the gRNA
sequence targeting the most prominent CTCF motif
(shown here in bold colored sequence). For the
aneuploid MCF7 cell line, the two most common
mutations are depicted.
(C) ChIP-qPCR showing reduction of the CTCF oc-
cupancy in D-CTCF K562, HCT-116, Jurkat, and
MCF7 cells. p values were generated with a Stu-
dent’s t test. Error bars represent the SD of the mean
from three technical replicates.
(D) qPCR showing reduction of endogenous MYC
mRNA levels inD-CTCF K562, HCT-116, Jurkat, and
MCF7 cells. p values were generated with a Stu-
dent’s t test. Error bars represent the SD of the mean
from three biological replicates.
See also Figure S2.perturbation model showed reduced proliferation for these four
cell types upon induction of CTCF-site deletions (Figures S2C–
S2G). These results indicate that the CTCF motif in the MYC
enhancer-docking site is necessary for CTCF binding, for high
levels of MYC expression and for cellular proliferation.
If the putativeMYC enhancer-docking site contributes to loop-
ing interactions with distal enhancers, then the loss of this site
should cause a decrease in DNA interactions between the
MYC promoter and the distal super-enhancers. We used chro-
mosome conformation capture combined with high-throughput352 Cell Reports 23, 349–360, April 10, 2018sequencing (4C-seq) to compare super-
enhancer interactions in K562 and HCT-
116 cells with normal or perturbed CTCF
binding motifs. The 4C-seq data in K562
cells indicated that the MYC enhancer-
docking site interacts predominantly with
distal super-enhancers located 0.3 Mb
and 2 Mb downstream of the MYC gene
and that the majority of these interactions
were significantly reduced when the puta-
tive CTCF motif was perturbed (Figures
3A and S3A). In order to control for any
direct effects of a genetic alteration near
the viewpoint, 4C-seq was performed with
a viewpoint placed in the downstream su-
per-enhancer. This showed clear interac-tions with the MYC enhancer-docking site as well as with the
nearby super-enhancer, and these interactions were signifi-
cantly reduced upon perturbation of the CTCF motif (Figures
3B and S3B). Similar results were obtained in HCT-116 cells,
where the viewpoint was centered on the super-enhancer
located0.4 Mb upstream of theMYC gene (Figure S3C). These
results showed that the CTCF site in the promoter-proximal re-
gion of MYC is important for optimal interaction with distal en-
hancers and supports the idea that this CTCF site functions as
an enhancer-docking site.
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Figure 3. Perturbation of the MYC Enhancer-Docking Site Reduces Looping to Super-Enhancers
(A) 4C analysis showing reduced looping of theMYC promoter proximal CTCF site to super-enhancers in CTCF motif deletion cells (DK562) versus unmodified
cells (K562). H3K27Ac ChIP-seq and CTCF ChIP-seq are shown in blue and purple colors respectively. Blowups show the 4C interactions for three K562 specific
super-enhancers. The 4C viewpoint is situated 112 base pairs upstream of the deleted loop-anchor region.
(B) 4C analysis showing reduced looping of the MYC promoter proximal CTCF site to super-enhancers in CTCF motif deletion cells (DK562) versus unmodified
cells (K562) using a viewpoint centered on themost distant super-enhancer downstream of theMYC gene. H3K27Ac ChIP-seq and CTCF ChIP-seq are shown in
blue and purple, respectively. Blowups show the 4C interactions at the MYC promoter and distant super-enhancer near the viewpoint. Shading represents the
90% confidence interval based on three biological replicates. Peak calls from the H3K27Ac ChIP-seq were used to define the regions to be quantified and are
indicated in gray boxes at the bottom of the panels. Boxplots show quantification of the reads per fragment for the indicated regions. p values were generated
using Student’s t test, and data pairs with a p value < 0.05 are indicated with an asterisk. Reads are shown in reads per million sequenced reads per base pair.
Typical enhancers and super-enhancers are shown as gray boxes and red boxes, respectively.
See also Figure S3.
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Figure 4. dCas9-Mediated Methylation of the CTCF Loop-Anchor Site Reduces MYC Expression in Tumor Cells
(A) Top panel shows CTCF ChIP-seq at the MYC gene region in HCT-116 cells. ChIP-seq reads are shown in reads per million sequenced reads per base pair.
Bottompanels shows a blowup of the700-bp region underneath the CTCF peak depicting the CTCFmotifs (blue arrows) and the gRNAs (red rectangles) used to
target dCas9-DNMT3A-3L to the enhancer anchor. Lollipop symbols indicate the location of CpGs that are assayed for methylation levels in (C).
(B) Schematic representation of the experiment. HCT-116 or K562 cells were transfected with plasmids encoding the dCAS9-DNMT3A-3L, GFP, and a gRNA
together with a plasmid encoding 2 additional gRNAs. HCT-116 or K562 cells were isolated by FACS after 2 days, and DNA and RNA were isolated.
(C) Methylation at MYC promoter loop-anchor site in untreated cells and cells transfected with dCas9-DNMT3A-3L in conjunction with the 5 indicated gRNAs.
(D) qPCR analysis ofMYCmRNA levels and fraction of methylated CpGs for untreated and dCas9-DNMT3A-3L + 5 gRNA transfected cells. Error bars represent
the SD of the mean for three biological replicates.
See also Figure S4.Loss ofMYC Expression with Methylation of Enhancer-
Docking Site
CTCF binding is abrogated when its sequence motif is methyl-
ated (Bell and Felsenfeld, 2000; Maurano et al., 2015), and the
MYC enhancer-docking site occurs within a CpG island that is
consistently hypomethylated in different tumor types as well as
in different normal tissues (Figures S4A and S4B). The recent
development of tools that permit site-specific DNA methylation
(Liu et al., 2016; Siddique et al., 2013) suggested a means to
disruptMYC expression bymethylation of the enhancer-docking
site. To achieve targeted methylation, we created a construct to
express a dCas9 fusion protein consisting of the catalytic
domain of DNMT3A and the interacting domain of DMNT3L.
This dCas9-DNMT3A-3L protein was targeted to the MYC
enhancer-docking site in K562 and HCT-116 cells using multiple354 Cell Reports 23, 349–360, April 10, 2018guide RNAs that span the region (Figures 4A and 4B). The
targeting of dCas9-DNMT3A-3L resulted in robust local DNA
methylation (Figure 4C) and a 40%–50% reduction in mRNA
levels in both cell types (Figure 4D). The methylated region likely
contains binding sites for additional TFs that may be sensitive
to DNA methylation, so it is possible that the reduced mRNA
levels are due to multiple factors. In order to test whether
disruption of TFs other than CTCF contribute to the reduction
in MYC mRNA levels, the dCas9-DNMT3A-3L was targeted
to the MYC enhancer-docking site in CTCF-site deleted
K562 cells. No further reduction of MYC mRNA levels was
observed under these conditions (Figures S4C and S4D), indi-
cating that loss of CTCF was amajor contributor to the observed
reduction of MYC expression upon targeted methylation of the
MYC enhancer-docking site. These results demonstrate that
epigenetic editing of the enhancer-docking site can reduceMYC
expression.
CTCF Enhancer-Docking Sites at Additional Genes
Previous genomic studies have noted that CTCF might
engender enhancer-promoter interactions at a minority of
genes (Banani et al., 2017; Nora et al., 2017; Splinter et al.,
2006; Zuin et al., 2014). We therefore identified the set of genes
whose promoter-proximal regions contain CTCF-bound sites
and that show evidence of enhancer interactions in K562,
Jurkat, and HCT-116 cells. We identified all active transcription
start sites (TSSs) that have at least one CTCF-bound site within
2.5 kb of the TSS that interacts with at least one enhancer. This
yielded between 555 and 1,108 TSSs with a nearby CTCF site
that loops to an active enhancer (Figure 5A; Table S2). We
define these TSSs as having a putative CTCF enhancer-dock-
ing site. The majority of TSSs identified in this analysis were
identified in only one cell type, with only 52 TSSs identified in
all three cell types (Figure 5B). Nonetheless, these putative
enhancer-docking sites tended to be constitutively bound by
CTCF in all three cell types, and the CTCF motifs in these sites
showed high sequence conservation (Figures 5C and 5D). This
suggests that these putative enhancer-docking sites are occu-
pied by CTCF regardless of interaction with active enhancers
and that differences in cell-type-specific enhancers are largely
responsible for differential use of enhancer-docking site genes
in these cells.
Gene ontology analysis of the genes with putative enhancer-
docking sites found different processes to be significantly en-
riched in each cell type, and these processes were dominated
by the cellular identity of the cell lines (Figure S5A; Table S3).
Common processes among the three cell types include cell cycle
and other cancer-related processes such as gene expression
and response to signaling (Figure S5A). A number of cancer-
associated genes were found, including TGIF1, VEGFA,
RUNX1, and PIM1 (Figure 5E), as well as others (Figure S5B).
We conclude that genes other than MYC are likely regulated by
CTCF-bound enhancer-docking sites and that these include
multiple cancer-associated genes.
DISCUSSION
Aberrant transcriptional activation of theMYC oncogene occurs
frequently in tumor cells and is associated with tumor aggres-
sion. MYC resides within a 2.8 Mb TAD and its aberrant activa-
tion is generally accomplished by acquisition of a super-
enhancer somewhere within that TAD. How these diverse can-
cer-specific super-enhancers loop long distances to specifically
interact withMYC has not been clear.We find that the diverse su-
per-enhancers commonly interact with, and depend on, a
conserved CTCF binding site located 2 kb upstream of the
MYC promoter. Because tumor super-enhancers can encom-
pass genomic regions as large as 200 kb, and CTCF occupies
sites that occur on average every 10 kb, there is considerable
opportunity for super-enhancers to adventitiously contain a
CTCF-bound site, which in turn could serve to interact with the
MYC CTCF site (Table S6). Thus, different tumor super-en-
hancers have the opportunity to form through diverse mecha-nisms throughout this large TAD and can exploit the MYC
CTCF site to interact with and activate MYC expression.
The concept that enhancer-promoter interactions generally
occur within larger chromosomal loop structures such as
TADs, which are themselves often formed by the interaction of
CTCF proteins bound to each of the TAD loop anchors (Dekker
and Mirny, 2016; Fraser et al., 2015; Gorkin et al., 2014a; Hnisz
et al., 2016a), is supported by the observations described
here. These larger loop structures tend to insulate enhancers
and genes within the CTCF-CTCF loops from elements outside
those loops. Constraining DNA interactions within CTCF-CTCF
loop structures in this manner may facilitate proper enhancer-
promoter contacts.
The evidence described here argues that diverse human tu-
mor cell super-enhancers depend on the MYC CTCF site for
optimal levels of enhancer-promoter looping and mRNA expres-
sion. A recent independent study in K562 cells used a tiling
CRISPR screen to systematically perturb the MYC locus and
also found that full MYC expression and cell proliferation is
dependent on this region (Fulco et al., 2016). However, deletion
of the 2 kb CTCF site has limited effects onMYC expression in
mice (Dave et al., 2017; Gombert and Krumm, 2009), and some
translocated enhancers can drive MYC expression in the
absence of this CTCF site (Shiramizu et al., 1991). There are
several potential explanations for these diverse results. It is
possible that the 2 kb CTCF site is important for optimal
MYC expression levels in human cells, but not in mice. It is
conceivable that the deletion of a region containing the CTCF
site can be compensated by features of the new enhancer land-
scape in the deletion mutations. Furthermore, additional mecha-
nisms normally involved in enhancer-promoter interactions,
such as YY1-YY1 interactions, may mask the loss of the CTCF
site in vivo; YY1 is present in the MYC promoter region and is
thus likely to contribute to DNA looping and expression (Wein-
traub et al., 2017).
Our studies suggest that an additional set of human genes,
beyond MYC, may utilize promoter-proximal enhancer-docking
sites to mediate cell-type-specific enhancer-promoter interac-
tions. Such CTCF-mediated enhancer-promoter interactions
are generally nested within larger CTCF-mediated loops that
would function as insulated neighborhoods. At these genes
with CTCF-mediated enhancer docking, the promoter-proximal
enhancer-docking sites tend to be constitutively bound by
CTCF and these binding sites tend to be highly conserved.
Indeed, two studies have reported that these genes tend to
lose expression upon perturbation of CTCF (Nora et al., 2017;
Zuin et al., 2014), consistent with a role for CTCF in enhancer-
promoter looping. Among these genes are cancer-associated
genes that likely employ this mechanism to engender interac-
tions with tumor-specific enhancers. For example, at CSNK1A1,
a drug target in acute myeloid leukemia (AML) tumor cells
(Ja¨ra˚s et al., 2014), VEGFA, which is upregulated in many can-
cers (Goel and Mercurio, 2013), and RUNX1, a well-defined
oncogene in AML (Deltcheva and Nimmo, 2017), the evidence
suggests that super-enhancers in these cancer cells use
a CTCF enhancer-docking mechanism to interact with the
oncogene. Thus, a CTCF-dependent enhancer-docking mecha-
nism, which presumably facilitates interaction with differentCell Reports 23, 349–360, April 10, 2018 355
RAD21 ChIA-PET 50kb
VEGFA
K562
CTCF
TESE
50kb
RUNX1
SMC1 ChIA-PET
Jurkat
CTCF
TESE
A
E
C D
B
50kbSMC1 HiChIP
HCT-116
CTCF
TESE TGIF1
CTCF motif
K562
M
ea
n 
P
ha
st
C
on
s
−100bp 5'3'+100bp
1.0
0.5
0.0
Jurkat
−100 5'3' +100
1.0
0.5
0.0
HCT-116
−100 5'3' +100
1.0
0.5
0.0
K562
Jurkat
HCT-116
interaction
enhancer
Expressed
transcripts
with CTCF
 at promoter E-P interaction
13251
10180
13437
6252
2151
3874
1108
813
555
transcript CTCF
K562
TSSs with putative enhancer-docking sites
by cell type
HCT-116
870105
52
81106
316
550
Jurkat
K562
active gene
 TSSs
with
consitutive
CTCF
with
enhancer-docking
site
8329
1038
712
101
Jurkat
10920
1962
480
75
HCT-116
10143
2000538
570
10kbRAD21 ChIA-PET
K562
CTCF
TESE PIM1
Figure 5. Putative Enhancer-Docking Sites Occur at Additional Genes with Prominent Roles in Cancer
(A) Identification of genes with putative enhancer-docking sites. Genes were filtered for their expression status, presence of a CTCF binding site within 2.5 kb of
the TSS and evidence of looping to an active enhancer, defined by H3K27Ac ChIP-seq.
(B) Venn-diagram showing the overlap of TSSs with putative CTCF enhancer docking in K562, HCT-116, and Jurkat cells.
(C) Venn-diagrams showing the number of TSSs from active genes, the number of these that exhibit putative CTCF enhancer-docking and how many of these
have a constitutive CTCF site within 2.5 kb of the TSS.
(D) Conservation analysis of the CTCFmotifs in the CTCF-bound elements in putative enhancer-docking sites. The mean 46-way PhastCons score of the highest
JASPAR scoring motifs in CTCF peaks within putative CTCF enhancer docking and their flanking regions are shown.
(E) Examples of genes with putative CTCF enhancer-docking sites from the different cell types analyzed. CTCF ChIP-seq peaks are shown as purple rectangles,
typical enhancers are shown as gray rectangles, and super-enhancers are shown as red rectangles. Black arrows indicate the CTCF sites that may facilitate
enhancer docking. The insulated neighborhood loop is shown in blue and loops internal to it are shown in purple. HCT-116 HiChIP interactions internal to the
neighborhood with an origami score of at least 0.9 and aminimum PET count of 15 are shown for the TGIF1 locus. Jurkat SMC1 ChIA-PET interactions internal to
the neighborhood with an origami score of at least 0.97 are shown for the RUNX1 locus. K562 RAD21 ChIA-PET interactions internal to the neighborhood with an
origami score of at least 0.9 and aminimumPET count of 30 are shown for the VEGFA locus. K562RAD21ChIA-PET interactions internal to the neighborhoodwith
an origami score of at least 0.9 and aminimum PET count of 30 are shown for the PIM1 locus. Data are from this study and two others (Hnisz et al., 2016a; Heidari
et al., 2014).
See also Figure S5.
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cell-specific enhancers during development, is exploited by can-
cer cells to dysregulate expression of prominent oncogenes.
MYC dysregulation is a hallmark of cancer (Bradner et al.,
2017). The c-MYC TF is an attractive target for cancer therapy
because of the role that excessive c-MYC levels play in a broad
spectrum of aggressive cancers (Felsher and Bishop, 1999; Jain
et al., 2002; Soucek et al., 2008), but direct pharmacologic inhi-
bition of c-MYC remains an elusive challenge in drug discovery
(Bradner et al., 2017). TheMYC enhancer-docking site, and pre-
sumably those of other oncogenes, can be repressed by dCas9-
DNMT-mediated DNA methylation. Oncogene enhancer-dock-
ing sites may thus represent a vulnerability in multiple human
cancers.
EXPERIMENTAL PROCEDURES
Further details and an outline for resources used in this work can be found in
Supplemental Experimental Procedures.
CRISPR/Cas9 Genome Editing
Genome editing was performed using CRISPR/Cas9 essentially as described
previously (Ran et al., 2013). The genomic sequences complementary to all
guide RNAs are listed in Table S4.
ChIP-Seq
ChIP was performed as described previously (Lee et al., 2006). Approxi-
mately 30 million cells were crosslinked for 10 min at room temperature by
the addition of one-tenth of the volume of 11% formaldehyde solution to
the growth media followed by 5 min quenching with 125 mM glycine. Cells
were washed twice with PBS, and then the supernatant was aspirated and
the cell pellet was flash frozen at 80C. 100 mL Protein G Dynabeads
(Thermo 10003D) were blocked with 0.5%BSA (w/v) in PBS. Magnetic beads
were bound with 40 mL anti-CTCF antibody (Millipore 07-729). Nuclei were
isolated as previously described (Lee et al., 2006) and sonicated in lysis
buffer on a Misonix 3000 sonicator for 5 cycles at 30 s each on ice (18–21
W) with 60 s on ice between cycles. Sonicated lysates were cleared once
by centrifugation and incubated overnight at 4Cwith magnetic beads bound
with antibody to enrich for DNA fragments bound by the indicated factor.
Beads were washed with wash buffers A, B, C, and D sequentially. DNA
was eluted, cross-links were reversed, and DNA was purified with phenol
chloroform extraction and ethanol precipitation. Libraries for Illumina
sequencing were prepared following the Illumina TruSeq DNA Sample
Preparation v2 kit and sequenced on the Illumina HiSeq 2500 for 40 bases
in single-read mode.
4C-Seq
A modified version of 4C-seq (van de Werken et al., 2012) was developed
(Supplemental Experimental Procedures). The major change was the ligation
is performed in intact nuclei (in situ). This change was incorporated because
previous work has noted that in situ ligation dramatically decreases the rate
of chimeric ligations and background interactions (Rao et al., 2014).
HiChIP
HiChIP was performed essentially as described (Mumbach et al., 2016).
10 million HCT116 cells were crosslinked for 10 min at room temperature by
the addition of one-tenth of the volume of 11% formaldehyde solution to the
growth media followed by 5-min quenching with glycine. Cells were washed
twice with PBS, and then the cell pellet was flash frozen in liquid nitrogen.
Frozen samples were processed according to protocol (Supplemental Exper-
imental Procedures).
Targeted Methylation and Bisulfite Sequencing
To perform targeted methylation, cells were transfected with a dCas9-
DNMT3A-3L construct and five guides. To generate the dCas9-DNMT3A-3Lconstruct, dCas9 was isolated from pSQL1658 (Addgene 51023) by PCR.
Cas9 was removed from pX330-Cas9 (Addgene 42230) and replaced by
DNMT3A-3L (Siddique et al., 2013). Guide RNAs used for targeting can be
found in Table S4.
Statistical Methods
ChIP-Seq Data Analysis
ChIP-seq datasets were generated for this study as well as collated from pre-
vious studies (Table S5) and were aligned using Bowtie (version 0.12.2) to the
human genome (build hg19, GRCh37) with parameter -k 1 -m 1 -n 2. We used
MACS version 1.4.2 with the parameter ‘‘-no-model-keep-dup=auto.’’ A p
value threshold of enrichment of 1e-09 was used.
4C Analysis
4C-seq reads were trimmed and mapped using bowtie with options -k 1 -m
1 against the hg19 genome assembly. We only used the reads from non-
blind fragments for further analysis. The normalized profile of each sample
was smoothened using a 6-kb running mean at 500-bp steps across the
genome. Quantification of the 4C signal counted the reads per fragment
per million sequenced reads in the super-enhancers or the CTCF MACS
peak calls.
HiChIP and ChIA-PET Data Analysis
Wedeveloped a new software pipeline and analytical method called origami to
process HiChIP and chromatin interaction analysis by paired-end tag
sequencing (ChIA-PET). The software and releases can be found at https://
github.com/younglab/origami using version alpha20160828. The ChIA-PET
datasets analyzed along with their corresponding linker sequence and called
interactions in and around the MYC TAD can be found in Table S4. Each
ChIA-PET datasets was processed as follows: the reads were first trimmed
and aligned using origami-alignment. Each end of a paired end tag (PET)
with a linker sequence were separately mapped to the hg19 genome assembly
using bowtie with the following options: -v 1 -k 1 -m 1. After alignment, the
separated PETs were re-paired in the final BAM output. After repairing,
all duplicated PETs within the data were removed. Peaks were called on
the re-paired ChIA-PET reads using MACS1 v1.4.2 with the following
parameters: -nolambda -nomodel -p 1e9.
DATA AND SOFTWARE AVAILABILITY
The accession number for the sequencing data reported in this paper is GEO:
GSE92881. The origami algorithm is accessible at https://github.com/
younglab/origami (version alpha20160828).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and six tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.03.056.
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